维普期刊资源整合服务平台（V6.5）

70篇 您的检索式：作者名="Dunleavy K"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	AngioimmunoblasticT cell lymphoma: pathobiological insights and clinicalimplications显示文摘	Dunleavy K Wilson WH Jaffe ES	2007	Curr Opin Hematol2007，14，4：	1
2	Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma显示文摘	Dunleavy K Pittaluga S Maeda LS	2013	N Engl J Med2013，368，：	1
3	Preliminary report ofmulticenter prospective phase D study of DA-EPOCH-R inmycrearranged aggressive B-cell lymphoma 显示文摘	Dunleavy K Fanale M Lacasce A	2014	ASH AnnualMeeting2014，，：	1
4	Phase Ⅱ study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers显示文摘	Wilson WH Dunleavy K Pittaluga S	2008	J Clin Oncol2008，26，16：	1
5	Police officer anxiety after occupational blood and body fluid exposure显示文摘	Dunleavy K Taylor A Gow J	2012	Occup Med(Lond)2012，62，5：	1
6	Angioimmunoblastic T- cell lymphoma: Immune modulation as a therapeutic strategy 显示文摘	Dunleavy K Wilson WH	2007	Leuk Lymphoma2007，48，3：	1
7	BCL-6 and rituximab in diffuse large B-cell lymphoma:where are we?显示文摘	Dunleavy K Davis RE Landgren O		0，，02：	1
8	The BCL-2 hiomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma显示文摘	Dunleavy K Staudt LM Wilson WH		0，，06：	1
9	Lymphomatoid granulomatosis-a single institute experience: pathologic findings and clinical correlations显示文摘	Song JY Piualuga S Dunleavy K	2015	Am J Surg Paihol2015，39，2：	1
10	The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma显示文摘	Dunleavy K Staudt LM Wilson WH	2007	Leuk Lymphoma2007，48，6：	1
11	Dose-adjusted EPOCH- rituximab therapy in primary mediastinal B-cell lymphoma显示文摘	Dunleavy K Pittaluga S Maeda LS	2013	N Engl J Med2013，368，15：	1
12	Borteziomibplus DA-EPOCH-rituximab followedby bortezomib maintenance versus observationin previously untreated mantle celllymphoma (MCL)显示文摘	Grant C Dunleavy K Tweito M	2011	Journal o f ClinicalOncology2011，29，15：	1
13	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma显示文摘	Dunleavy K Pittaluga S Czuczman M S	2009	Blood2009，113，24：	1
14	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma 显示文摘	Dunleavy K Pittaluga S Czuczman MS	2009	Blood2009，113，24：	1
15	Phase II study of dose-adjusted EPOCH and rituximah in untreated diffuse large B-cell lymphoma with analysis of germinal center and post- germinal center biomarkers 显示文摘	Wilson WH Dunleavy K Pittaluga S	2008	J Clin Oncol2008，26，16：	1
16	Phase Ⅱ study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers显示文摘	WilsonWH Dunleavy K Pittaluga S	2008	J Clin Oncol2008，26，16：	1
17	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lyrnphoma显示文摘	Dunleavy K Pittaluga S Myron S	2009	Blood2009，113，：	1
18	Phase I1 study of dose - adjusted EPOCH and rituximab in untreated diffuse large B - cell lymphoma with analysis of germinal center and post - germinal center biomarkers 显示文摘	Wilson WH Dunleavy K	2008	J Clin Oncol2008，26，16：	1
19	Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications 显示文摘	Dunleavy K Wilson WH Jaffe ES	2007	Curt Opin Hematol2007，14，4：	1
20	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma显示文摘	Dunleavy K Pittaluga S Czuczman MS	2009	Blood2009，113，24：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示